细胞毒性T细胞
癌症研究
软组织肉瘤
组蛋白脱乙酰酶抑制剂
组蛋白脱乙酰基酶
化学
医学
体外
肉瘤
病理
组蛋白
生物化学
基因
作者
Wenjie Gong,Lei Wang,Maria‐Luisa Schubert,Christian Kleist,Brigitte Neuber,Sanmei Wang,Mingya Yang,Angela Hückelhoven‐Krauss,Depei Wu,Anita Schmitt,Carsten Müller‐Tidow,Hiroshi Shiku,Michael W. Schmitt,Leopold Sellner
出处
期刊:Biomedicines
[Multidisciplinary Digital Publishing Institute]
日期:2022-02-03
卷期号:10 (2): 373-373
被引量:5
标识
DOI:10.3390/biomedicines10020373
摘要
Adoptive cell therapy with NY-ESO-1-specific T cells is a promising option for the treatment of soft tissue sarcoma (STS) but achieves only transient tumor control in the majority of cases. A strategy to optimize this cell therapeutic approach might be the modulation of the expression of the cancer-testis antigen NY-ESO-1 using histone deacetylase inhibitors (HDACis). In this study, the ex vivo effect of combining NY-ESO-1-specific T cells with the clinically approved pan HDACis panobinostat or vorionstat was investigated. Our data demonstrated that STS cells were sensitive to HDACis. Administration of HDACi prior to NY-ESO-1-specific T cells exerted enhanced lysis against the NY-ESO-1+ STS cell line SW982. This correlated with an increase in the NY-ESO-1 and HLA-ABC expression of SW982 cells, as well as increased CD25 expression on NY-ESO-1-specific T cells. Furthermore, the immune reactivity of NY-ESO-1-specific CD8+ T cells in terms of cytokine release was enhanced by HDACis. In summary, pretreatment with HDACis represents a potential means of enhancing the cytotoxic efficacy of NY-ESO-1-specific T cells against NY-ESO-1-positive STS.
科研通智能强力驱动
Strongly Powered by AbleSci AI